Three years after the Food and Drug Administration told MannKind Corp. to run additional tests on Afrezza, the inhalable diabetes medication has finally been approved. Afrezza is an insulin powder that users inhale from a single-use cartridge before or within 20 minutes of eating a meal, The Associated Press reports.
It is meant for those suffering from type 2 diabetes, the most common type of the disease, which stops the body from properly using insulin. As obesity rates soar worldwide, so too have the rates of those suffering from the chronic condition. Several other inhalable insulin medications have tanked either on the market or in development, including one from Pfizer Inc. in 2007 and another by Eli Lilly & Co. a year later. The FDA has noted that Afrezza should not be used as a long-term alternative to longer-acting insulin injections.
-
From Da Vinci to a golden toilet: a history of museum heistsIn the Spotlight Following the ‘spectacular’ events at the Louvre, museums are ‘increasingly being targeted by criminal gangs’
-
Can Gen Z uprisings succeed where other protest movements failed?Today's Big Question Apolitical and leaderless, youth-led protests have real power but are vulnerable to the strongman opportunist
-
The allegations of Christian genocide in NigeriaThe Explainer West African nation has denied claims from US senator and broadcaster
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstancesSpeed Read
-
Western mountain climbers allegedly left Pakistani porter to die on K2Speed Read
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governorSpeed Read
-
Los Angeles city workers stage 1-day walkout over labor conditionsSpeed Read
-
Mega Millions jackpot climbs to an estimated $1.55 billionSpeed Read
-
Bangladesh dealing with worst dengue fever outbreak on recordSpeed Read
-
Glacial outburst flooding in Juneau destroys homesSpeed Read
-
Scotland seeking 'monster hunters' to search for fabled Loch Ness creatureSpeed Read
